Open AccessA Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
Author(s) -
Maren de Vries,
Adil Mohamed,
Rachel A Prescott,
Ana M. Valero-Jimenez,
Ludovic Desvignes,
Rebecca E. O’Connor,
Claire M. Steppan,
Joseph C. Devlin,
Ellie Ivanova,
Alberto Herrera,
Austin Schinlever,
Paige Loose,
Kelly V. Ruggles,
Sergei B. Koralov,
Annaliesa S. Anderson,
Joseph Binder,
Meike Dittmann
Publication year - 2021
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.01819-20
Subject(s) - vero cell , a549 cell , biology , protease inhibitor (pharmacology) , virology , coronavirus , antiviral drug , viral life cycle , pharmacology , lopinavir , viral entry , viral replication , in vitro , virus , viral load , covid-19 , medicine , biochemistry , disease , infectious disease (medical specialty) , antiretroviral therapy
The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy.